Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone425-205-2900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.62 million
Profitability
Miscellaneous
Employees202
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Alder Biopharmaceuticals (NASDAQ:ALDR) Frequently Asked Questions
What is Alder Biopharmaceuticals' stock symbol?
Alder Biopharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."
How were Alder Biopharmaceuticals' earnings last quarter?
Alder Biopharmaceuticals Inc (NASDAQ:ALDR) released its quarterly earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($0.72) EPS for the quarter, beating analysts' consensus estimates of ($0.99) by $0.27. View Alder Biopharmaceuticals' Earnings History.
When is Alder Biopharmaceuticals' next earnings date?
What price target have analysts set for ALDR?
12 equities research analysts have issued twelve-month price targets for Alder Biopharmaceuticals' shares. Their forecasts range from $14.00 to $21.00. On average, they anticipate Alder Biopharmaceuticals' share price to reach $18.44 in the next twelve months. This suggests that the stock has a possible downside of 2.4%. View Analyst Price Targets for Alder Biopharmaceuticals.
What is the consensus analysts' recommendation for Alder Biopharmaceuticals?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alder Biopharmaceuticals in the last year. There are currently 9 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Alder Biopharmaceuticals.
What are Wall Street analysts saying about Alder Biopharmaceuticals stock?
Here are some recent quotes from research analysts about Alder Biopharmaceuticals stock:
- 1. According to Zacks Investment Research, "Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. " (10/15/2019)
- 2. Mizuho analysts commented, "We maintain our Neutral rating on the shares as we see limited catalysts for the shares prior to FDA approval; financing overhang as well as risks associated with commercial launch." (5/3/2019)
- 3. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating and $14 PT on ALDR. Today (5/2), Alder reported 1Q19 earnings, including cash and STI, of $498.5M. With the BLA submission of eptinezumab (epti’) accepted by the FDA and with a PDUFA date set for February 2020, the company expects to launch the drug by early next year (1Q20), and we believe its cash on hand will enable it to fund building out a right-sized" neurology/headache-specialist focused sales force, as well as other launch prep this year; it started with the recent hiring of a chief commercial officer." (5/2/2019)
Has Alder Biopharmaceuticals been receiving favorable news coverage?
Press coverage about ALDR stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Alder Biopharmaceuticals earned a coverage optimism score of -1.9 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Alder Biopharmaceuticals.
Are investors shorting Alder Biopharmaceuticals?
Alder Biopharmaceuticals saw a decline in short interest in September. As of September 30th, there was short interest totalling 12,050,000 shares, a decline of 27.5% from the August 30th total of 16,630,000 shares. Based on an average trading volume of 2,640,000 shares, the days-to-cover ratio is currently 4.6 days. Approximately 17.0% of the company's stock are sold short. View Alder Biopharmaceuticals' Current Options Chain.
Who are some of Alder Biopharmaceuticals' key competitors?
Some companies that are related to Alder Biopharmaceuticals include Beigene (BGNE), ACADIA Pharmaceuticals (ACAD), Amarin (AMRN), Horizon Therapeutics (HZNP), The Medicines (MDCO), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), United Therapeutics (UTHR), Blueprint Medicines (BPMC), Mirati Therapeutics (MRTX), FibroGen (FGEN), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), Allakos (ALLK) and Reata Pharmaceuticals (RETA).
What other stocks do shareholders of Alder Biopharmaceuticals own?
Who are Alder Biopharmaceuticals' key executives?
Alder Biopharmaceuticals' management team includes the folowing people:
- Dr. John A. Latham, Co-Founder & Chief Scientific Officer (Age 59)
- Mr. Larry K. Benedict, Principal Accounting Officer & Exec. VP (Age 58)
- Dr. Jeffrey T. L. Smith, Managing Director of Alder Biopharmaceuticals Limited (Age 59)
- Mr. Robert W. Azelby, Pres, CEO & Director (Age 51)
- Mr. Carlos Campoy, Chief Financial Officer
Who are Alder Biopharmaceuticals' major shareholders?
Alder Biopharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Havens Advisors LLC (0.10%). Company insiders that own Alder Biopharmaceuticals stock include Erin Lavelle, James B Bucher, Jeffrey T L Smith, John A Latham and Mark James Litton. View Institutional Ownership Trends for Alder Biopharmaceuticals.
Which institutional investors are buying Alder Biopharmaceuticals stock?
How do I buy shares of Alder Biopharmaceuticals?
Shares of ALDR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Alder Biopharmaceuticals' stock price today?
One share of ALDR stock can currently be purchased for approximately $18.89.
How big of a company is Alder Biopharmaceuticals?
Alder Biopharmaceuticals has a market capitalization of $1.58 billion and generates $1.62 million in revenue each year. The biopharmaceutical company earns $-296,430,000.00 in net income (profit) each year or ($4.87) on an earnings per share basis. Alder Biopharmaceuticals employs 202 workers across the globe.View Additional Information About Alder Biopharmaceuticals.
What is Alder Biopharmaceuticals' official website?
How can I contact Alder Biopharmaceuticals?
Alder Biopharmaceuticals' mailing address is 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA, 98011. The biopharmaceutical company can be reached via phone at 425-205-2900 or via email at [email protected]
MarketBeat Community Rating for Alder Biopharmaceuticals (NASDAQ ALDR)
MarketBeat's community ratings are surveys of what our community members think about Alder Biopharmaceuticals and other stocks. Vote "Outperform" if you believe ALDR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALDR will underperform the S&P 500 over the long term. You may vote once every thirty days.
